RVL Pharmaceuticals PLC (O1P.MU)
Chart Events
Performance Outlook
| Previous Close | 1.2200 |
| Open | 1.2200 |
| Bid | 1.1100 x N/A |
| Ask | 1.2100 x N/A |
| Day's Range | 1.2200 - 1.2200 |
| 52 Week Range | 0.9700 - 2.9400 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for O1P.MU
Related Research
- Zacks Small Cap Research
RVLP: Year Closes on a Strong Note
By John Vandermosten, CFA NASDAQ:RVLP READ THE FULL RVLP RESEARCH REPORT Fourth Quarter Preliminary Results Following our initiation of RVL Pharmaceuticals, plc (NASDAQ:RVLP) with a valuation of $3.60 per share, management provided an update on fourth quarter revenues which are expected to be $12.1 million, a 21% sequential increase over third quarter levels and a 323% year over year increase. We
- Simply Wall St.
Recent gains in RVL Pharmaceuticals plc (NASDAQ:RVLP) help add back some value on insider purchases worth US$1.6m, still down US$160k
Insiders who bought US$1.6m worth of RVL Pharmaceuticals plc ( NASDAQ:RVLP ) stock in the last year have seen some of...
- GlobeNewswire
RVL Pharmaceuticals plc Announces Preliminary Fourth Quarter Sequential Growth of 21% and Full Year 2022 UPNEEQ® Net Product Sales
-- Expects fourth quarter 2022 preliminary UPNEEQ net product sales of approximately $12.1 million, representing an increase of 21% over the third quarter 2022, and approximately $36.5 million for full year 2022 -- -- Approximately 4,300 cumulative unique medical aesthetics practices had placed orders for UPNEEQ through the end of the fourth quarter 2022, a 23% increase from the end of the third quarter 2022 -- BRIDGEWATER, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq:
